Article

Daunorubicin May Produce, Contribute to Long-Term Remission, Survival in Patients with Newly Diagnosed High-Risk/Secondary AML

Daunorubicin and cytarabine liposome for injection is a dual-drug liposomal encapsulation of cytarabine and daunorubicin approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.

After a 5-year follow-up, improved overall survival (OS) was maintained in a phase 3 study of daunorubicin and cytarabine liposome for injection (CPX-351, Vyxeos), supporting evidence that the therapy has the ability to produce or contribute to long-term remission and survival in older patients with newly diagnosed high-risk/secondary acute myeloid leukemia (AML), according to a poster at the 2020 ASCO Virtual Scientific Program.

Daunorubicin and cytarabine liposome for injection is a dual-drug liposomal encapsulation of cytarabine and daunorubicin approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.

The phase 3 study, NCT01696084, evaluated patients aged 60-75 years with newly diagnosed high-risk/secondary AML and found that daunorubicin and cytarabine liposome for injection significant improved median OS versus conventional 7+3 with a comparable safety profile.

Patients were randomized 1:1 to receive ≤2 induction cycles of daunorubicin and cytarabine liposome for injection as a 90-minute infusion on Days 1, 3, 5 or 7+3. Further, patients who achieved complete remission (CR) or CR with incomplete platelet or neutrophil recovery could receive up to 2 consolidation cycles. Patients could receive a hematopoietic cell transplant (HCT) at the physician’s discretion, and patients were followed until death or up to 5 years following randomization.

Three hundred and nine patients were randomized to daunorubicin and cytarabine liposome for injection or 7+3, and the survival rate at 5 years was higher for daunorubicin and cytarabine liposome for injection versus 7+3.

The most common primary cause of death was progressive leukemia in both arms, among the studied patients who died. After a median follow-up of 60.65 months, improved median OS with daunorubicin and cytarabine liposome for injection versus 7+3 was maintained.

HCT was received by 35% and 25% of patients after daunorubicin and cytarabine liposome for injection versus 7+3. Among these patients, the survival rate at 5 years was higher for daunorubicin and cytarabine liposome for injection versus 7+3 and median OS landmarked from the HCT date was not reached for daunorubicin and cytarabine liposome for injection versus 10.25 months for 7+3.

REFERENCE

Lancet JF, Uy GL, Newell LF, et al. Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. Poster presented at: 2020 ASCO Virtual Scientific Program; May 29-31, 2020; Tampa, FL. Accessed June 2, 2020. Doi: 10.1200/JCO.2020.38.15_suppl.7510.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com